Search - tctmd.com

Displaying 1 - 19 of 19

Sort: Relevancy | Date

News Conference News ACC 2025

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

Caitlin E. Cox

March 30, 2025

Presentation ACC 2025

Dapagliflozin after Transcatheter Aortic Valve Implantation

Presenter: Sergio Raposeiras-Roubin

March 29, 2025

Another Win for TAVI in Low-to-Intermediate Risk Patients

News Conference News ACC 2024

Another Win for TAVI in Patients at Low-to-Intermediate Risk: DEDICATE-DZHK6

Yael L. Maxwell

April 08, 2024

News Conference News ACC 2023

Self-Expanding TAVI Holds Up to Surgery Out to 3 Years in Low-Risk Patients

Todd Neale

March 05, 2023

News Conference News ACC 2022

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

Todd Neale

April 05, 2022

News Conference News ACC 2021

Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC

Michael O'Riordan

May 17, 2021

News Conference News ACC 2020

Edoxaban May Be Alternative to Warfarin After Surgical Valve Implantation or Repair

L.A. McKeown

April 07, 2020

News Conference News ACC 2020

New Patient-Focused TAVR Quality Score Rolling Out to US Hospitals

Michael O'Riordan

April 06, 2020

News Conference News ACC 2020

Early Data Support TAVR in Bicuspid Valves, but Questions Remain

Michael O'Riordan

March 29, 2020

News Conference News ACC 2019

Low-Risk Trials Cement a Role for TAVR Alongside—or in Place of—Surgery

Michael O'Riordan

March 17, 2019

News Conference News ACC 2019

ACC 2019: A Smartwatch, Low-risk TAVR, and Bempedoic Acid Are Hoping for Luck Saint Paddy’s Day Weekend

Shelley Wood

March 11, 2019

News Conference News ACC 2018

NOTION: 5-Year Outcomes for TAVR Match SAVR in Low-Risk Patients

Shelley Wood

March 10, 2018

News Conference News ACC 2017

TAVR for Bicuspid Aortic Stenosis? Registry Offers Clues to Safety, Outcomes

Shelley Wood

March 24, 2017

News Conference News ACC 2017

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

Michael O'Riordan

March 19, 2017

News Conference News ACC 2017

Live From Washington: ACC 2017, Day One

Shelley Wood

March 17, 2017

News Conference News ACC 2017

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

Todd Neale

March 17, 2017

News Conference News ACC 2012

Study Looks at Long-term Mortality Predictors in TAVR Patients

Jason Kahn

March 27, 2012

Presentation ACC 2012

Long-Term Outcomes Following Transcatheter Aortic Valve Implantation: Insights on Prognostic Factors and Valve Durability from the Canadian Multicenter Experience

Presenter: Josep Rod?s-Cabau

March 24, 2012

News Conference News ACC 2012

ADVANCE: TAVR with CoreValve Safe, Effective at 6 Months

March 24, 2012

Advertisement

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

Dapagliflozin after Transcatheter Aortic Valve Implantation

Another Win for TAVI in Patients at Low-to-Intermediate Risk: DEDICATE-DZHK6

Self-Expanding TAVI Holds Up to Surgery Out to 3 Years in Low-Risk Patients

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC

Edoxaban May Be Alternative to Warfarin After Surgical Valve Implantation or Repair

New Patient-Focused TAVR Quality Score Rolling Out to US Hospitals

Early Data Support TAVR in Bicuspid Valves, but Questions Remain

Low-Risk Trials Cement a Role for TAVR Alongside—or in Place of—Surgery

ACC 2019: A Smartwatch, Low-risk TAVR, and Bempedoic Acid Are Hoping for Luck Saint Paddy’s Day Weekend

NOTION: 5-Year Outcomes for TAVR Match SAVR in Low-Risk Patients

TAVR for Bicuspid Aortic Stenosis? Registry Offers Clues to Safety, Outcomes

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

Live From Washington: ACC 2017, Day One

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

Study Looks at Long-term Mortality Predictors in TAVR Patients

Long-Term Outcomes Following Transcatheter Aortic Valve Implantation: Insights on Prognostic Factors and Valve Durability from the Canadian Multicenter Experience

ADVANCE: TAVR with CoreValve Safe, Effective at 6 Months

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content